Integromat Evolves to Make, Expanding Its Vision to Empower Creators to Innovate Without Limits
Today, no-code integration platform Integromat, launched “Make”. Make represents the name of the brand, business, and the new product—a visually intuitive platform that lets you design, build, and automate anything from simple workflows to complex processes, without coding. The new brand name and identity has evolved alongside the new product to capture the broader vision for a world where everyone has the power to innovate without limits.
“Make captures the evolution of our platform, the spirit of our customers, and reflects one of the most transformational trends of our era: from rigid, top-down, repetitive jobs to flexible, empowering, and meaningful work. Our users aren’t just connecting apps or automating workflows; they are creatively responding to workplace challenges by building solutions,” said Ondřej Gazda, CEO of Make. “Put simply, we’ve realized our users aren’t just users, they’re Makers.”
Make is paving a new future for no-code and redefining what it means to be a visual platform. No-code tools are often represented by the typical visual drag-and-drop feature; for Make, visual means something different. Make allows teams to visualize, modify, and collaborate on processes that scale as quickly as their organization. Make offers an intuitive and playful experience, which sets it further apart from other automation tools.
“No-code tools are just that; they enable users to build and automate without writing any code. Make offers much more: a visual language that democratizes development, makes processes tangible and fosters team collaboration, regardless of technical skills,” said Patrik Simek, CTO of Make. “It’s also fun and exciting to create on Make. Once you realize what’s possible—it feels like there are no limits. Empowering humans to innovate doesn’t just change the future of how we work—it also changes the world.”
Small businesses, startups, scale-ups, teams and enterprises all around the world can now create powerful solutions #withMake to scale their businesses faster than ever.
The Make platform is based upon a new architectural foundation that provides dramatically increased scalability and performance. It also includes new, lol highly requested capabilities with the familiar visual experience Integromat customers love. Users can also benefit from the ability to run their critical processes hosted in a region of their choice, Europe or North America (with more regions to come).
Integromat was acquired by Celonis in 2020. Now, one and a half years later, Make is launched as its own business unit within Celonis. Integromat will remain as a legacy product offering through 2022. All existing customers will have the opportunity to seamlessly upgrade to Make over the course of next year. New customers can register for Make and begin to take advantage of the new platform immediately.
About Make
Make is the leading visual platform for anyone to design, build, and automate anything—from tasks and workflows to apps and systems—without the need for coding skills. Make enables individuals, teams, and enterprises across all verticals to create powerful custom solutions that scale their businesses faster than ever. Make powers over 500,000+ organizations around the globe. Learn more about Make at www.make.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220222005231/en/
Contact information
Shiran Brodie
Head of Marketing
press@make.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
BeOne Medicines Presents New SEQUOIA Study Results Reinforcing BRUKINSA’s Differentiated Profile with or without Venetoclax in Frontline CLL at ASCO 202531.5.2025 15:00:00 EEST | Press release
BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today will present new data from the Arm C and D cohorts of the pivotal, global Phase 3 SEQUOIA trial of BRUKINSA® (zanubrutinib). The findings underscore the strong and consistent efficacy of BRUKINSA across CLL patient types, including high-risk mutation status. These data will be presented in two rapid oral presentations at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, IL. Data from the Arm D of SEQUOIA demonstrate that treatment with BRUKINSA plus venetoclax has the potential to drive progression-free survival and overall deep and durable responses across the frontline CLL patient spectrum, including patients with high-risk mutational status. The best undetectable minimal residual disease (uMRD) rate in peripheral blood at a sensitivity level 10-4 was 59%. These efficacy responses observed in Arm D, despite the high proportion of high-risk patients enrolled, are in
You Up? Grindr’s “Right Now” Goes Global30.5.2025 16:00:00 EEST | Press release
Grindr, the Global Gayborhood in Your Pocket™ with more than 14.6M average monthly active users, today announced the global launch of Right Now, their newest intent-based feature designed to instantly connect people looking for immediate encounters. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250530651954/en/ Grindr's Right Now feature. Right Now is a real-time feed—separate from the app’s main grid that displays profiles—where Grindr users can post text and share photos displayed for one hour, letting other like-minded users know exactly what they’re looking for. “Right Now empowers our users to find exactly what they want, when they want it – without the guesswork,” said AJ Balance, Chief Product Officer at Grindr. “We built this intention-based feature based on feedback from our community so they can connect with like-minded people without wasting time on mismatched expectations. The response to our initial March launc
CAR T Vision Coalition Launches with Ambitious Goal to Double Patients Treated with the Curative Potential of CAR T-cell Therapy by 203030.5.2025 15:00:00 EEST | Press release
Today an international coalition announces the launch of CAR T Vision to unite stakeholders around the shared ambition that every eligible patient should have the opportunity for cure with CAR T-cell therapy. By 2030, the aim is to double the proportion of eligible patients treated with CAR T-cell therapy. As outlined in the new roadmap report, the coalition will work to address access challenges and drive meaningful change in the CAR T-cell therapy healthcare ecosystem with a focus on three critical priorities: increasing awareness and understanding of CAR T-cell therapy; expanding resources and capacity to deliver CAR T-cell therapy; and developing sustainable and innovative financing approaches to manage the costs of treatment and care. “Despite CAR T-cell therapy being available in the United States for nearly seven years in large B-cell lymphoma, only approximately two out of 10 eligible patients with some advanced blood cancers ever receive CAR T-cell therapy,” said Miguel Perale
Indian Educationist Dr. Achyuta Samanta Recognised With Research Institute in His Name at CUNY, USA30.5.2025 12:17:00 EEST | Press release
In a noteworthy development underscoring growing academic collaboration between India and the United States, the City University of New York (CUNY) has launched a dedicated research platform—the Achyuta Samanta India Initiative of the CUNY CREST Institute (ASIICCI). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250529012005/en/ Dr. Milton Santiago, President of Bronx Community College, and Dr. Achyuta Samanta, Founder of KIIT & KISS, jointly inaugurate the Achyuta Samanta India Initiative of CUNY CREST Institute (ASIICCI) with a ribbon-cutting ceremony in New York. Named after Dr. Achyuta Samanta, a noted Indian educationist and social worker, the initiative focuses on academic research in Indian social and educational sectors, with a particular lens on Odisha. This marks one of the rare instances of a living Indian being honoured with such a naming in an American public university system. Dr. Samanta, who hails from Odisha
FDA Grants De Novo Clearance for Reflow Medical's Spur ® Peripheral Retrievable Stent System30.5.2025 07:08:00 EEST | Press release
Reflow Medical, Inc., a leading developer of innovative medical devices focused on complex cardiovascular disease, announced that the U.S. Food and Drug Administration (FDA) has granted De Novo clearance for the company’s Spur Peripheral Retrievable Stent System, a unique clinical solution for the treatment of de novo or restenotic lesions following predilatation in patients with infrapopliteal arterial disease. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250529610368/en/ The first and only retrievable stent system that features a self-expanding stent with an integrated dilatation balloon catheter on an over-the-wire system. It is designed for controlled lesion penetration and treatment through a series of radially expandable spikes. Known as Retrievable Scaffold Therapy (RST), the spikes on the Spur Stent penetrate the lesion to increase the acute luminal diameter and modify the lesion morphology to change vessel complia
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom